XML 89 R77.htm IDEA: XBRL DOCUMENT
v3.22.4

LICENSE AGREEMENTS (Details) € in Thousands |  |  |  |  | 1 Months Ended | 3 Months Ended | 12 Months Ended
--- | --- | --- | --- | --- | --- | --- | ---
Jul. 20, 2022 USD ($) | Aug. 05, 2021 USD ($) | Nov. 30, 2020 USD ($) | Jul. 30, 2020 USD ($) | Jul. 31, 2022 USD ($) | Aug. 31, 2021 USD ($) | Dec. 31, 2020 USD ($) | Dec. 31, 2022 USD ($) | Mar. 31, 2021 USD ($) | Mar. 31, 2021 EUR (€) | Dec. 31, 2020 USD ($) | Dec. 31, 2020 EUR (€) | Dec. 31, 2022 USD ($) | Dec. 31, 2022 EUR (€)
Organization And Basis Of Presentation [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Asset purchase agreement, variable consideration |  |  |  |  |  |  |  | $ 30,000,000 |  |  |  |  | $ 30,000,000 |
Payments to refund license agreement deposits | $ 3,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Qilu Pharmaceutical Co., Ltd. | Licensing Agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |
Organization And Basis Of Presentation [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment |  |  |  | $ 12,000,000 |  |  |  |  |  |  |  |  |  |
Total milestone payments |  |  |  | $ 23,000,000 |  |  |  |  |  |  |  |  |  |
Royalty payment, percentage |  |  |  | 12.00% |  |  |  |  |  |  |  |  |  |
University of Zurich |  |  |  |  |  |  |  |  |  |  |  |  |  |
Organization And Basis Of Presentation [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty payment obligation, percent |  |  |  |  |  |  |  |  |  |  |  |  | 4.00% | 4.00%
Third party maximum ownership, percent |  |  |  |  |  |  |  |  |  |  |  |  | 10.00% | 10.00%
Third party minimum ownership, percent |  |  |  |  |  |  |  |  |  |  |  |  | 2.00% | 2.00%
Expenses related to achievement of development milestone |  |  |  |  |  | $ 500,000 | $ 300,000 |  |  |  |  |  |  |
University of Zurich | Collaborative Arrangement, Revenue Based on Clinical Development Milestone |  |  |  |  |  |  |  |  |  |  |  |  |  |
Organization And Basis Of Presentation [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
License agreement, amount payable upon achievement of specified milestone |  |  |  |  |  |  |  |  |  |  |  |  | $ 500,000 |
Micromet AG |  |  |  |  |  |  |  |  |  |  |  |  |  |
Organization And Basis Of Presentation [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty payment obligation, percent |  |  |  |  |  |  |  |  |  |  |  |  | 3.50% | 3.50%
Expenses related to achievement of development milestone |  |  |  |  |  |  |  |  | $ 600,000 | € 500 | $ 900,000 | € 700 | $ 51,770 | € 50
Potential milestone payments |  |  |  |  |  |  |  |  |  |  |  |  | $ 2,600,000 | € 2,400
License agreement, royalty payment, reduction, conditions not met |  |  |  |  |  |  |  |  |  |  |  |  | 1.50% | 1.50%
License maintenance fees | € |  |  |  |  |  |  |  |  |  |  |  |  |  | € 50
XOMA Ireland Limited |  |  |  |  |  |  |  |  |  |  |  |  |  |
Organization And Basis Of Presentation [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
License agreement, amount payable upon achievement of specified milestone |  |  |  |  |  |  |  |  |  |  |  |  | $ 250,000 |
Royalty payment obligation, percent |  |  |  |  |  |  |  |  |  |  |  |  | 2.50% | 2.50%
Third party maximum ownership, percent |  |  |  |  |  |  |  |  |  |  |  |  | 50.00% | 50.00%
Third party minimum ownership, percent |  |  |  |  |  |  |  |  |  |  |  |  | 1.75% | 1.75%
Roche |  |  |  |  |  |  |  |  |  |  |  |  |  |
Organization And Basis Of Presentation [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Other receivable, asset purchase agreement |  |  |  |  |  |  |  | 30,000,000 |  |  |  |  | $ 30,000,000 |
Proceeds from execution of asset purchase agreement |  |  |  |  | $ 40,000,000 |  |  |  |  |  |  |  |  |
Roche | EBI-031 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Organization And Basis Of Presentation [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Other receivable, asset purchase agreement |  |  |  |  | $ 70,000,000 |  |  |  |  |  |  |  |  |
Qilu Pharmaceutical Co., Ltd. |  |  |  |  |  |  |  |  |  |  |  |  |  |
Organization And Basis Of Presentation [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
License agreement, amount payable upon achievement of specified milestone |  |  |  |  |  |  |  |  |  |  |  |  | $ 200,000 |
Royalty period |  |  |  | 12 years |  |  |  |  |  |  |  |  |  |
License termination fee |  |  |  |  |  | $ 1,400,000 |  |  |  |  |  |  |  |
License termination payment |  |  |  |  |  |  |  | $ 1,200,000 |  |  |  |  |  |
MENA License Agreement | Licensing Agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |
Organization And Basis Of Presentation [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment |  |  | $ 3,000,000 |  |  |  |  |  |  |  |  |  |  |
Eczacibasi Pharmaceuticals Marketing Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |
Organization And Basis Of Presentation [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payments |  | $ 2,000,000 |  |  |  |  |  |  |  |  |  |  |  |
Transaction price |  | $ 1,500,000 |  |  |  |  |  |  |  |  |  |  |  |
Eczacibasi Pharmaceuticals Marketing Agreement | TURKEY |  |  |  |  |  |  |  |  |  |  |  |  |  |
Organization And Basis Of Presentation [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty revenue, percentage |  | 0.30 |  |  |  |  |  |  |  |  |  |  |  |

X
- Definition Asset Purchase Agreement, Variable Consideration + References No definition available. + Details
Name: | sesn_AssetPurchaseAgreementVariableConsideration
Namespace Prefix: | sesn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Business Combination, Long-term Purchase Commitment, Milestone Amount + References No definition available. + Details
Name: | sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount
Namespace Prefix: | sesn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Business Combination, Royalty Payment Percent + References No definition available. + Details
Name: | sesn_BusinessCombinationRoyaltyPaymentPercent
Namespace Prefix: | sesn_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative Arrangement, Royalty Period + References No definition available. + Details
Name: | sesn_CollaborativeArrangementRoyaltyPeriod
Namespace Prefix: | sesn_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition License Agreement, Amount Payable Upon Achievement of Specified Milestone + References No definition available. + Details
Name: | sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone
Namespace Prefix: | sesn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition License Agreement, Milestone Achievement Expense + References No definition available. + Details
Name: | sesn_LicenseAgreementMilestoneAchievementExpense
Namespace Prefix: | sesn_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition License Agreement, Percentage of Royalty On Net Product Sales + References No definition available. + Details
Name: | sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales
Namespace Prefix: | sesn_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition License Agreement, Percentage of Royalty on Net Product Sales, Minimum + References No definition available. + Details
Name: | sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum
Namespace Prefix: | sesn_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition License Agreement, Percentage Rate Requiring Reduction in the Amount of Royalties Owed + References No definition available. + Details
Name: | sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed
Namespace Prefix: | sesn_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition License Agreement, Royalty Payment, Reduction, Conditions Not Met, Percent + References No definition available. + Details
Name: | sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent
Namespace Prefix: | sesn_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition License Agreement, Termination Expense + References No definition available. + Details
Name: | sesn_LicenseAgreementTerminationExpense
Namespace Prefix: | sesn_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition License Agreement, Termination Payment + References No definition available. + Details
Name: | sesn_LicenseAgreementTerminationPayment
Namespace Prefix: | sesn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition License Maintenance Fees + References No definition available. + Details
Name: | sesn_LicenseMaintenanceFees
Namespace Prefix: | sesn_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Organization And Basis Of Presentation [Line Items] + References No definition available. + Details
Name: | sesn_OrganizationAndBasisOfPresentationLineItems
Namespace Prefix: | sesn_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Other Receivable, Asset Purchase Agreement + References No definition available. + Details
Name: | sesn_OtherReceivableAssetPurchaseAgreement
Namespace Prefix: | sesn_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Payments to Refund License Agreement Deposits + References No definition available. + Details
Name: | sesn_PaymentsToRefundLicenseAgreementDeposits
Namespace Prefix: | sesn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Proceeds From Execution Of Asset Purchase Agreement + References No definition available. + Details
Name: | sesn_ProceedsFromExecutionOfAssetPurchaseAgreement
Namespace Prefix: | sesn_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Revenue Recognition, Milestone Method, Potential Milestone Payments + References No definition available. + Details
Name: | sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments
Namespace Prefix: | sesn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Royalty Revenue, Percentage + References No definition available. + Details
Name: | sesn_RoyaltyRevenuePercentage
Namespace Prefix: | sesn_
Data Type: | xbrli:pureItemType
Balance Type: | na
Period Type: | instant

X
- Definition The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (b)(1) -URI https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585 + Details
Name: | us-gaap_PaymentsToAcquireBusinessesGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of transaction price allocated to performance obligation that has not been recognized as revenue. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=sesn_QiluPharmaceuticalCoLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sesn_UniversityOfZurichMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sesn_MicrometAGMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sesn_XOMAIrelandLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sesn_RocheMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=sesn_EBI031Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sesn_QiluPharmaceuticalCoLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sesn_MENALicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sesn_EczacibasiPharmaceuticalsMarketingAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_TR
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |